277 results about "Cell lymphoma" patented technology

The invention is applicable to the technical field of clinical medicine, provides a clinical multi-modal cancer drug response prediction method based on feature reconstruction, constructs a clinical multi-modal model for drug response prediction of diffuse large B-cell lymphoma, and aims to predict the drug response of diffuse large B-cell lymphoma by integrating gene sequencing and clinical multi-modal data. And accurate drug reaction prediction is realized. The model adopts an end-to-end multi-stage processing flow: firstly, extracting gene features through TransP-Net, and processing multi-modal clinical data by using a clinical information encoder; then, pseudo-gene features are generated through a clinical-genome filling module to deal with the data missing problem; and finally, multi-modal deep fusion is realized through a clinical information decoder, and a prediction result is output. According to the method, data characteristics and working processes in a real clinical environment are fully considered, two conditions of complete gene data and missing gene data can be processed at the same time, and the method has a good clinical transformation prospect and application value.

The invention discloses a diffuse large B-cell lymphoma segmentation system based on deep learning, and the system comprises a data collection module which is used for collecting PET and CT images of a patient; the double-branch encoder module is used for processing PET and CT images respectively; the cross-modal feature cross fusion module is used for extracting positioning clues from the CT anatomical features by taking the PET metabolic features as queries; taking CT structure characteristics as query, and screening PET high-metabolism regions; the global-attention suppression module is used for extracting global context features, performing down-sampling, remodeling input features into a low-dimensional matrix, then performing self-attention calculation, generating a sparse weight matrix for the input features based on a full connection layer, and then performing sparse attention calculation; and finally, fusing the two attention calculation results and outputting enhanced features. And the multi-scale jump connection module is used for fusing the encoder features and the decoder features and recovering spatial details.

Purinostat mesylate (PM) for preventing and treating diffuse large B-cell lymphoma (DLBCL), an analogue thereof, a drug for combined use, and the use. PM exhibits excellent in-vivo and in-vitro anti-tumor therapeutic effects on DLBCL (DEL and DHL) subtypes with poor prognosis, DLBCL subtypes having TP53 deletion and mutation combined with a plurality of poor prognosis gene mutations, and DLBCL having TP53 mutation with double expressors, which are superior to that of most existing DLBCL clinical therapy plans. A doublet or triplet therapy of PM with rituximab, R-CHOP, venetoclax and R-CHP also exhibits excellent in-vivo therapeutic effects against DLBCL and a plurality of subtypes. Thus, PM and the drug for combined use have an important clinical significance for the DLBCL and a plurality of subtypes.

The invention belongs to the technical field of prognosis models, and particularly relates to a diffuse large B-cell lymphoma risk prognosis model based on lactic acid metabolism related genes. The model construction comprises the following steps: S1, data acquisition and processing; s2, constructing a prognosis model; s3, verifying and evaluating the prognosis model; and S4, application of a prognosis model. GSE10846 and GSE87371 data sets are used for screening lactic acid metabolism related genes (LMRGs), a prognosis risk model is constructed and verified, and association of the prognosis risk model with clinical pathological characteristics, immune characteristics and treatment response is disclosed.

The invention relates to the field of anti-tumor drugs, and discloses an anti-diffuse large B-cell lymphoma pharmaceutical composition, a preparation method and application thereof, the composition comprises azacitidine and Sanilisoma, the composition can improve the accumulation amount of VDUP1 protein in a cell nucleus through the combination of the methylation effect of DNMT3b on VDUP1 protein and the inhibition of XPO1 activity by Sanilisoma, and the anti-diffuse large B-cell lymphoma pharmaceutical composition can be used for preparing anti-diffuse large B-cell lymphoma. The chemotherapy effect is remarkably improved, the sensitivity of the DLBCL to the Sanisole is remarkably improved, and particularly, the pharmaceutical composition has a remarkable curative effect on R / R DLBCL patients.

Bifunctional compounds, which find utility as modulators of B-cell lymphoma 6 protein (BCL6; target protein), are described herein. In particular, the bifunctional compounds of the present disclosure contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand that binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation / inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

The invention discloses an early diagnosis marker for B-cell lymphoma, a cross-species screening method based on lamprey and application, and relates to the technical field of molecular diagnosis. In the prior art, tissue biopsy is strong in invasiveness, and a traditional marker is low in early detection rate; in order to solve the problems that a large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large- When the expression quantity of the gene in a sample is greater than or equal to 1.8 times of that of a normal B cell (HMY2. CIR), the lymphoma is judged to be positive, and the minimally invasive early diagnosis efficiency is remarkably improved.

The invention relates to the technical field of biomedicine, in particular to a molecular target for treating recurrent refractory diffuse large B-cell lymphoma and application of the molecular target. According to the invention, a molecular target CSNK1E for treating recurrent refractory diffuse large B-cell lymphoma is excavated; compared with existing traditional targets of other drugs for recurrent lymphoma, the CSNK1E has a remarkable expression difference in the recurrent DLBCL, and it is indicated that the CSNK1E possibly has more remarkable advantages in treatment of the recurrent DLBCL.

The invention provides inter alia methods of treating cancer comprising administering to a subject a cytidine triphosphate synthase 1 (CTPS1) inhibitor and a B-cell lymphoma 2 (BCL2) inhibitor.

The invention relates to the technical field of biological medicine detection, and discloses tsRNA for predicting, diagnosing or monitoring diffuse large B-cell lymphoma, a kit and application of the tsRNA. The marker comprises one or more of six tsRNAs including tsRNA-Leu-CAG, tsRNA-Pro-CG, tsRNA-Gln-CTG, tsRNA-Cys-GCA, tsRNA-Leu-AAG, tsRNA-Lys-CTT and the like, and the nucleotide sequence of the marker is as shown in SEQ ID NO. 1-6; the nucleotide sequence of the marker is as shown in SEQ ID NO. By detecting the change of the expression level of tsRNA in peripheral blood serum, early diagnosis, dynamic monitoring of treatment response and prognosis evaluation of DLBCL can be realized.

The invention discloses a prognosis evaluation method and system for diffuse large B-cell lymphoma. According to the method, firstly, a gene module closely related to lipid metabolism is screened from DLBCL transcriptome data through weighted gene co-expression network analysis (WGCNA), and then eight key prognosis genes including FNDC1, IL22RA2, C15orf48, OMD, MFAP2, BC017398, CXCL6 and TNFAIP6 are identified from the module by adopting multi-step regression analysis (single factor Cox, LASSO and multi-factor Cox). A risk scoring model is constructed based on the expression levels and regression coefficients of the genes, and DLBCL patients can be divided into a high-risk group and a low-risk group with significant survival differences. The risk score and the clinical pathological factors are further integrated to construct a column graph, and individualized survival probability prediction can be achieved. The invention further provides a corresponding prognosis evaluation system, electronic equipment and a storage medium. An independent data set verifies that the prognosis model has excellent prediction performance and clinical practical value.

Provided herein are compositions and methods for treating a relapsed or refractory hematologic cancer in a human patient in need thereof. The methods entail administering to the patient a daily dose of about 10 mg to about 75 mg of cerdulatinib or a pharmaceutically acceptable salt thereof, wherein the patients suffer one or more of a B-cell malignancy, chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) or other transformed FL and / or have relapsed or not responded to a prior chemotherapy.

The present invention provides a combined chimeric antigen receptor targeting CD19 and CD20 and application thereof. Specifically, the present invention provides a combined chimeric antigen receptor targeting CD19 and CD20, which comprises a scFv targeting CD19 and CD20, a hinge region, a transmembrane region, and an intracellular signaling domain. The present invention provides a nucleic acid molecule encoding the chimeric antigen receptor and a corresponding expression vector, a CAR-T cell, and applications thereof. The experimental results show that the chimeric antigen receptor provided by the present invention shows extremely high killing ability against tumor cells. The chimeric antigen receptor of the present invention targets CD19 and / or CD20 positive cells and can be used to treat CD19 and / or CD20 positive B-cell lymphoma, leukemia and other diseases.

The present disclosure relates to topical formulations and methods of treating skin diseases using topical formulations comprising a JAK 1 / 2 inhibitor, which is ruxolitinib, or a pharmaceutically acceptable salt thereof, and an organic amine pH adjusting agent. The skin diseases for treatment include, but are not limited to, psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratoderma, pachyonychia congenita, steatocystoma multiplex, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and a disorder of keratinization. The organic amine pH adjusting agent is a tertiary amine or an alkanol amine.

The invention provides a biomarker composition based on plasma metabonomics and application of the biomarker composition in early diagnosis of nasal extrinsic N / KT cell lymphoma, and relates to the technical field of biomarkers. According to the present invention, for the first time, it is provided that the 2-Methylbutyl beta-D-glucose acid, the 4-(2, 3-dihydro-1, 4-benzodioxin-6-yl) glucose acid and the 4-(octyloxyl) glucose acid can be adopted as the biomarkers for distinguishing the chronic sinusitis patient from the nasal knot external N / KT cell lymphoma patient, and the application of the 2-Methylbutyl beta-D-glucose acid, the 4-(2, 3-dihydro-1, 4-benzodioxin-6-yl) glucose acid, the 4-(2, 3-dihydro-1, 4-benzodioxin-6-yl) glucose acid, the 4-(2, 3-dihydro-1, 4-benzodioxin-6-yl) glucose acid and the 4-( According to the invention, a single-factor prediction model / combined factor prediction model NKTCL early diagnosis model AUCgt is constructed by taking the three biomarkers as characteristics and combining a random forest algorithm; 0.9, sensitivity gt; the specificity is gt; and the kit has relatively high accuracy, sensitivity and specificity for diagnosing the N / KT cell lymphoma outside the nasal knots, and is high in disease diagnosis and prediction capability. According to the method, stepped improvement of diagnosis efficiency is directly achieved through the synergistic effect of the multi-dimensional plasma metabonomics markers and algorithm suitability optimization, and a new normal form with high precision and clinical feasibility is provided for early screening of tumors.

The invention discloses an application of NF-kappa B and IRF4 in prognosis evaluation of diffuse large B-cell lymphoma, relates to the technical field of disease prognosis and molecular biology, provides a marker for prognosis evaluation of diffuse large B-cell lymphoma, and relates to the application of NF-kappa B and IRF4 in prognosis evaluation of diffuse large B-cell lymphoma. The invention relates to application of a substance for detecting the marker in claim 1 in preparation of a product for prognosis evaluation of diffuse large B-cell lymphoma, and provides a medicine for treating diffuse large B-cell lymphoma. By detecting the marker, the malignancy degree of the DLBCL can be more accurately analyzed, a reliable prognosis evaluation basis is provided for clinicians, and accurate prognosis evaluation is carried out; through targeting NF-kappa B and MUM1 dual-blocking therapeutic drugs, the prognosis of patients is improved, the life quality and the survival rate of the patients are improved, and novel therapeutic drugs are developed; a new breakthrough is brought to diagnosis, treatment and prognosis evaluation of the DLBCL, and potential clinical application value is achieved.

Disclosed herein are synthetic nanoparticles, pharmaceutical compositions, kits, or methods for treating and / or preventing cancer. In some embodiments, the synthetic nanoparticles and / or pharmaceutical compositions comprises a pH sensitive liposome, an apolipoprotein, and andrographolide or derivative thereof. In some embodiments, the synthetic nanoparticles are delivered to a subject for treatment of cancer. In some embodiments, the cancer is T-cell lymphoma or B-cell lymphoma.

The present invention relates to anti-CD 103 antibodies, as well as use of these antibodies in diagnosis, prognosis, monitoring, and treatment of diseases. Also disclosed is an imaging agent comprising the anti-CD 103 antibody and a detectable label, wherein the antibody either does not block CD 103 binding to E-cadherin or at least partially blocks CD 103 binding to E-cadherin. The methods of treatment involve administering the anti CD 103 antibody which may be optionally coupled to a cytotoxic agent. Diseases to be treated include e.g. Hairy Cell leukemia, HCLv, intestinal and extraintestinal lymphomas, enteropathy-associated T-cell lymphoma (EATL), T-lymphoblastic leukemia / lymphoma (T-ALL), T-cell prolymphocytic leukemia (T-PLL), adult T cell leukemia / lymphoma (ATLL), mycosis fungoides (ME), anaplastic large cell lymphoma ALCL, cutaneous T-cell lymphoma (CTCL), Sezary Syndrome (SS), Alzheimer's disease, Parkinson's disease or multiple sclerosis.

The application provides use of a compound A or a pharmaceutically acceptable salt thereof as a Bruton's tyrosine kinase (BTK) inhibitor in preparation of a drug for treating a BTK-related tumor disease. In vitro and in vivo test results show that the compound A has good inhibitory activity on BTK kinase, good inhibitory activity on human B-cell lymphoma cells with high BTK expression, and good in vivo anti-tumor activity. In addition, the compound A has good pharmacokinetic properties and metabolic stability, and can be used for developing a drug preparation for treating a BTK-related tumor disease, and has important clinical application value.

The present invention relates to methods of treating B-cell proliferative disorders, e.g., primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL), by administering glofitamab in combination with gemcitabine and oxaliplatin. Further the invention related to an optimized corticosteroid prophylaxis for glofitamab resulting in lower incidence of cytokine release syndrome (CRS).

The present disclosure relates generally to mutations in T cell lymphoma, and methods of use of the mutations in T cell therapy.

Provided herein are methods for monitoring, identifying, evaluating circulating tumor DNA (ctDNA) for treating a subject or monitoring a subject having cancer, and related methods and uses thereof. In some embodiments, the disease or disorder is relapsed or refractory B-cell lymphoma (BCL).

The invention belongs to the technical field of medicines, and particularly relates to application of dioscin combined with chidamide in diffuse large B-cell lymphoma. Specifically, research finds that the dioscin can significantly inhibit DLBCL cell proliferation and induce cell cycle arrest and apoptosis by up-regulating PINK1 / Parkin mediated mitochondrial autophagy and enhancing H3K27 acetylation mediated epigenetic regulation. When the chidamide and the dioscin are combined for use, a synergistic effect can be generated, and by further increasing the H3K27ac level, the cell apoptosis induction effect is enhanced, and the in-vivo and in-vitro anti-tumor activity on DLBCL is remarkably improved. The invention provides a novel and efficient DLBCL combined treatment scheme, and provides a new pharmaceutical composition and theoretical support for clinical diagnosis and treatment of DLBCL, so that the application has good practical application value.

The invention provides application of zinc pyrithione and copper pyrithione in treatment of lymphoma, and discovers that zinc pyrithione and copper pyrithione have an obvious inhibition effect on proliferation of diffuse large B-cell lymphoma cells, and the inhibition effect is relatively good. Therefore, the zinc pyrithione can be used for preparing the medicine for treating the lymphoma, especially diffuse large B-cell lymphoma, and is used for clinically treating the lymphoma. The invention provides a new scheme and strategy for treatment of lymphoma, especially diffuse large B-cell lymphoma, provides a new choice for drug-resistant patients, and is relatively low in treatment cost.

This disclosure provides a method for treating lymphoma, the method comprising administering a bispecific CD20xCD3 antibody to a patient in need, wherein the patient is selected based on an improvement in the level of circulating tumor (ct) DNA. In some embodiments, this disclosure provides a method for identifying lymphoma patients who may respond well to a therapy comprising a bispecific CD20xCD3 antibody.

T-cell malignancies are a broad, heterogenous group of diseases and include T-cell lymphomas and T-cell leukemias. T-cell lymphomas are a heterogeneous group of malignancies involving T lymphocytes and generally characterized by a poor prognosis. Among them, cutaneous T-cell lymphomas involve primarily the skin. Mycosis fungoides and Sézary syndrome are the most frequent cutaneous T-cell lymphomas. The inventors showed that both circulating malignant and non-malignant T cells express CD51 in patients with Sézary syndrome. CD51 therefore appears as a useful diagnostic, prognostic and follow-up marker, and as a potential therapeutic target in T-cell lymphomas.

The application discloses an index combination for identifying diffuse large B-cell lymphoma and application thereof. The index combination is composed of gender, age and eight oligosaccharide chains, namely NGA2F, NG2FB, NG1A2F-1, NG1A2F-2, NA2F, NA2FB, NA3Fb and NA4Fb. The application also provides a prediction model, a prediction system, a computer readable storage medium and a kit constructed based on the index combination. Experimental results show that the prediction model has a sensitivity of 88.06%, a specificity of 92.98% and an AUC of 0.949 in identifying diffuse large B-cell lymphoma in a verification set. The application realizes, for the first time, non-invasive, rapid and high-accuracy identification of diffuse large B-cell lymphoma based on blood oligosaccharide chains combined with clinical indexes, and provides a brand-new tool for auxiliary differential diagnosis of patients with lymph node enlargement.

The invention relates to the technical field of biological medicines, in particular to a polypeptide targeting B cell lymphoma cells, a targeting effect conjugate and application of the polypeptide and the targeting effect conjugate. Wherein the peptide chain length of the polypeptide targeting the B-cell lymphoma cells is 12 amino acids, and the polypeptide is selectively and specifically combined with the B-cell lymphoma cells. The targeting effect conjugate is formed by connecting polypeptide and pro-apoptotic peptide through a connecting peptide. The pro-apoptotic peptide can induce programmed death of target cells by destroying a mitochondrial membrane structure. The molecular weight of the polypeptide is small, the chemical synthesis process is simple, convenient and efficient, high consistency between different batches of products can be ensured in the synthesis process, and a guarantee is provided for subsequent quality control. The small molecular structure is also convenient for sequence optimization and terminal modification, can create extremely favorable conditions for subsequent structure-function relationship research and pharmaceutical development work, and is helpful for accelerating the research and development process of novel therapeutic drugs.

The present disclosure relates to anti-CD79b antibodies and anti-CD79b antibody drug conjugates (anti-CD79b ADCs) comprising thereof, where the anti-CD79b ADCs further comprise a topoisomerase 1 inhibitor (Top1i) drug as a payload. The present disclosure further relates to methods of using such anti-CD79b ADCs for treating B-cell non-Hodgkin lymphoma (B-NHL), diffuse large B cell lymphoma (DLBCL), Burkitt's lymphoma, mantle cell lymphoma, and follicular lymphoma.